SCHEMBL6823396

SCHEMBL6823396

Cc1cc(C)c2c3c([nH]c2c1)CCCC3

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 2/20 0.41
SMN1; SMN2 Q16637 4/20 0.40
MAPT P10636 6/20 0.39
LMNA P02545 4/20 0.39
THRB P10828 1/20 0.39
ALOX15 P16050 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38
POLB P06746 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
HTT P42858 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4793856 0.80 SIRT2 (0.47) KDM4EHSD17B10LMNATHRBALOX15
SCHEMBL11496500 0.80 NISCH (0.45) KDM4EHSD17B10MAPTLMNATHRB
Hydrochloric Acid SCHEMBL4792857 0.78 TAAR1 (0.46) KDM4EHSD17B10LMNATHRBALOX15
SCHEMBL28549389 0.73 SMN1; SMN2 (0.50) EGFRKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL10099057 0.73 MAPT (0.57) KDM4EALDH1A1HSD17B10SMN1; SMN2MAPT
SCHEMBL28559488 0.73 SMN1; SMN2 (0.50) EGFRKDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL28961387 0.73 GRIN2D (0.48) KDM4EALDH1A1HSD17B10MAPTGRIN2D
SCHEMBL29588654 0.73 GRIN2D (0.48) KDM4EALDH1A1HSD17B10MAPTGRIN2D
SCHEMBL11499238 0.72 BAZ2B (0.52) MAPTLMNAPOLB
SCHEMBL20780028 0.71 MAPT (0.56) KDM4EALDH1A1HSD17B10SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067999-A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands ASTRAZENECA AB (SE) 2004-04-08 US disclosed
EP-1358157-A1 CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS AstraZeneca AB (SE) 2003-11-05 EP disclosed
WO-2002051806-A1 CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067999-A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands NPY5R, NPY1R, NPY2R EGFR 300/4885KDM4E 2632/4885ALDH1A1 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.